CLX · 10-Q · 2026Q3 · Full report

Acquisition / Partnership / Divestiture

CLOROX CO /DE/ · 2026-11-02 · Importance 91 · Surprise 92

Clorox’s GOJO acquisition, whose business operates as Clorox Purell ProCare, contributed to year-over-year sales and volume growth in the quarter ended September 30, 2026. The company reported $1,175 million of notes and loans payable, primarily U.S. commercial paper, to finance the GOJO acquisition and a Venture Agreement termination payment. Interest expense increased $29 million year over year, primarily because of incremental borrowings to fund GOJO. The quarter included $26 million of GOJO acquisition and integration costs, including inventory step-up, transaction, legal-entity, operational, manufacturing, and information-technology integration costs.

Key facts

• Clorox said the recent GOJO acquisition reflects its commitment to reduce volatility, accelerate sales growth and structurally improve margins. source
• Clorox’s interest expense increased by $29 million, primarily due to incremental borrowings to fund the GOJO acquisition. source
• Clorox identified risks that GOJO integration may not achieve anticipated benefits and synergies, including cost savings and growth opportunities, when expected or at all. source
• Clorox identified GOJO integration risks from adapting to its B2B operating model, including customer concentration, distributor and institutional-customer consolidation, and potential channel conflict with Clorox’s consumer business. source
• Clorox identified increased regulatory exposure from GOJO products subject to U.S. Food and Drug Administration oversight, including cosmetics and over-the-counter drugs. source
• Clorox identified potential unexpected costs, expenses, litigation and impairment charges related to the GOJO acquisition. source